Trial reportBone marrow transplantation2015
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Guideline
- Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study.Journal of clinical medicine · 2026Article
- Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?Annals of hematology · 2025Article
- Current Treatment Strategies for Multiple Myeloma at First Relapse.Journal of clinical medicine · 2025Review
- Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life study.HemaSphere · 2024Article
- Article
- Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy.Frontiers in oncology · 2024Review
- The efficacy and safety of second salvage autologous transplantation in myeloma patients.Pathology oncology research : POR · 2024Article
- Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience.Bone marrow transplantation · 2023Article
- Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Review
- The first relapse in multiple myeloma: how to pick the next best thing.Hematology. American Society of Hematology. Education Program · 2022Article
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.Cancers · 2021Article
- Comparison of single and double autologous stem cell transplantation in multiple myeloma patients.Open medicine (Warsaw, Poland) · 2021Article
- Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway.Oncology letters · 2020Article
- The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant.Bone marrow transplantation · 2018Article
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Haematologica · 2018Review
- Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.Bone marrow transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the most common first-line treatment for patients with multiple myeloma (MM) under 65 years of age. A second ASCT at first relapse is frequently used but is challenged by the use of novel drugs. We retrospectively studied the outcome of second-line treatment in MM patients from the Nordic countries with relapse after first-line HDT and ASCT. Patients that underwent a second ASCT (n=111) were compared with patients re-treated with conventional cytotoxic drugs only (n=91) or with regimens including novel drugs (proteasome inhibitors and/or immunomodulatory drugs) (n=362) without a second ASCT. For patients receiving a second ASCT median overall survival was 4.0 years compared with 3.3 years (P<0.001) for the group treated with novel drugs and 2.5 years (P<0.001) for those receiving conventional cytotoxic drugs only. A second ASCT also resulted in a significantly longer second time to progression and a significantly longer time to next treatment. We conclude that, irrespective of the addition of novel drugs, MM patients in first relapse after ASCT still appear to benefit from a second ASCT. A second ASCT should be considered for all physically fit patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.